On July 17, Japan’s Cabinet adopted the 2020 Basic Policy on Economic and Fiscal Management and Reform (honebuto). Its initial text suggested the government’s position to carry out its first off-year drug price revision next April as well as its…
HOME > COMMENTARY
COMMENTARY
- COMMENTARY／Korosho to Embark on Japanese Version of Sentinel Initiative
September 7, 2009
- COMMENTARY／Wholesalers Need to Analyze Causes of Their Failure
August 24, 2009
- COMMENTARY／Hisamitsu Aims at Growth by Fusing Its and Noven's Technologies
August 24, 2009
- COMMENTARY／Permitting MSs to Take MR Cert. Exam Offers New Business Opportunity to Wholesalers
August 3, 2009
- COMMENTARY／Fair Profits Are Essential to Spread Regenerative Medicine
August 3, 2009
- Hitech Drugs Open the Window to the Future- With Special Focus on Development and Marketing -(1)
July 20, 2009
- Hitech Drugs Open the Window to the Future- With Special Focus on Development and Marketing -(2)
July 20, 2009
- COMMENTARY／Global Pharmas Enhance Their Presence in Japan
July 13, 2009
- COMMENTARY／Additional Price Cuts for Long-listed Original Drugs
June 29, 2009
- COMMENTARY／Clinical Applications of ADCs Coming Closer to Reality
June 29, 2009
- SURVEY／RLS Takes Almost Four Years before Being Diagnosed
June 22, 2009
- COMMENTARY／JSHP to Promote Use of Generics
June 8, 2009
- COMMENTARY／Combination Drugs Becoming a "Boom"
June 1, 2009
- COMMENTARY／Clearer Criteria Needed for Patent Period Restoration
May 4, 2009
- EMTs Allowed to Administer Epipen
April 27, 2009
- COMMENTARY／Why Does the Use of Generics Not Increase?
April 27, 2009
- COMMENTARY／Medway Data Falsification to Make Blood Product Self-Sufficiency Difficult
April 20, 2009
- The First Round Results of GE Amlodipine (2)- Making No Surprise Moves Leads to Success -
April 6, 2009
- COMMENTARY／Worst Scenario Coming True due to Heated Competition among Wholesalers
March 23, 2009
- Unexpected Demand for ActHIB Causes Shortage of Supply
March 16, 2009
ページ
Since last year, Japan has seen a number of stock-outs and shortages of generic drugs attributable to API supply disruptions…
Nearly a year after the introduction of the Ministry of Health, Labor and Welfare’s (MHLW) drug promotion guidelines in April…
Advancements in modified oligonucleotide technologies has been the key driver behind a spate of approvals in the oligonucleotide therapeutics space…
Japan’s key reimbursement policy panel on December 20 approved an outline of its FY2020 drug pricing reform next April, with…
The Ministry of Health, Labor and Welfare (MHLW) on November 27 added to the NHI price list Japan’s first biosimilars of Avastin (bevacizumab), Nesp (darbepoetin alfa), and Forteo (teriparatide). The NHI prices of first biosimilars are set at 70% of…
A total of 51 new drugs joined the NHI price list in 2019, which are expected to generate combined peak sales of 373 billion yen, according to Jiho’s tally of data submitted to a key reimbursement policy panel. The relatively…
Some seven years in the making, Japan’s Ministry of Health, Labor and Welfare (MHLW) finally rolled out a cost-effectiveness assessment…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…
In a change striking to the very core of the traditional Japanese salaryman, “We are seeing the coronavirus ushering in a new way of working… and I think it’s about time,” says Ivan Tselichtchev, Professor of Economics at the Niigata…